ESSA Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Year	Current	2023	2022	2021	2020	2019	2018	2017	2016	2015
Market Capitalization	280	136	80	352	143	19	4	8	75	171
Market Cap Growth	-	69.89%	-77.20%	145.62%	635.97%	345.80%	-48.26%	-88.70%	-56.42%	-
Enterprise Value	138	-12	-87	157	65	-30	-4	12	66	170
PE Ratio	-11.29	-5.13	-2.28	-9.56	-6.11	-1.53	-0.37	-1.88	-5.68	-17.71
PB Ratio	1.99	0.94	0.48	1.81	1.81	0.40	0.48	-1.97	-139.12	38.47
P/FCF Ratio	-13.50	-6.89	-2.86	-13.84	-8.44	-1.59	-0.43	-0.49	-4.88	-12.68
P/OCF Ratio	-13.50	-6.89	-2.86	-13.84	-8.44	-1.59	-0.43	-0.49	-4.88	-12.85
EV/EBITDA Ratio	-5.81	0.45	2.48	-4.28	-2.81	2.51	0.41	-3.50	-5.48	-17.80
EV/EBIT Ratio	-5.79	0.45	2.47	-4.26	-2.80	2.51	0.41	-3.46	-5.45	-17.72
EV/FCF Ratio	-6.92	0.61	3.11	-6.18	-3.81	2.48	0.43	-0.72	-4.29	-12.56
Debt / Equity Ratio	0.00	0.00	0.00	0.00	0.00	0.08	0.69	-1.86	-	-
Debt / EBITDA Ratio	-0.01	0.00	-0.01	-0.01	0.00	-0.31	-0.59	-2.24	-	-
Debt / FCF Ratio	-0.02	0.00	-0.01	-0.01	0.00	-0.30	-0.62	-0.46	-	-
Quick Ratio	40.37	42.48	72.50	49.79	65.58	9.68	4.58	1.06	2.48	2.60
Current Ratio	40.75	42.57	73.17	50.28	66.73	9.74	4.66	1.34	2.76	3.39
Interest Coverage	-5618.16	-3827.97	-2560.84	-1656.96	-37.40	-20.10	-11.72	-4.59	-12.85	-102.21
Return on Equity (ROE)	-17.40%	-17.30%	-19.90%	-21.90%	-36.60%	-43.90%	-171.40%	165.40%	-511.30%	-301.00%
Return on Assets (ROA)	-17.00%	-17.00%	-19.50%	-21.40%	-34.70%	-36.10%	-77.10%	-41.20%	-113.90%	-164.80%
Return on Capital (ROIC)	-22.59%	-22.05%	-22.09%	-19.11%	-29.66%	-23.06%	-69.83%	-294.85%	3484.04%	-229.70%
Earnings Yield	-9.23%	-19.51%	-43.76%	-10.46%	-16.37%	-65.54%	-266.34%	-53.31%	-17.59%	-5.65%
FCF Yield	-7.72%	-14.52%	-34.91%	-7.22%	-11.85%	-62.93%	-234.01%	-205.65%	-20.50%	-7.89%
Buyback Yield / Dilution	-0.13%	-0.12%	-14.44%	-71.45%	-166.13%	-84.68%	-213.86%	-8.16%	-46.59%	-16.99%
Total Shareholder Return	-0.13%	-0.12%	-14.44%	-71.45%	-166.13%	-84.68%	-213.86%	-8.16%	-46.59%	-16.99%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).